secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001437749-26-010030
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Q4 net loss $5.2M, cash $140.4M; ALXN1840 NDA planned mid-2026
----------------------------------------------------------------------

- Q4 2025 net loss $5.2M ($0.61/sh) vs $10.9M ($2.23) YoY; full-year net loss $13.7M ($1.85/sh) vs $15.6M.
- Cash, equivalents and short-term investments $140.4M at Dec 31, 2025, expected to fund operations through Dec 31, 2027.
- NDA submission for ALXN1840 (Wilson disease) planned mid-2026; abstracts accepted at EASL 2026 and AAN 2026.
- Completed underwritten public offering generating ~$91.9M after concurrent stock repurchase in 2025.
- Appointed Susan Rodriguez as Chief Commercial and Strategy Officer for potential ALXN1840 launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926010030/0001437749-26-010030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926010030/mnpr20260326_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-010030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer